Australians will receive free coronavirus vaccines being developed by Queensland scientists

Modesto Morganelli
Luglio 20, 2020

New Delhi: The largest human trial of the Corona vaccine COVAXIN is scheduled to begin today at AIIMS, New Delhi.

For a period of 150 days the volunteers will be kept under observation.

The volunteers ought to be aged between 18 and 55 years and should not have any comorbidities.

The human trial is a partnership between Sinopharm's China National Biotec Group (CNBG), Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42) and the Abu Dhabi Department of Health.

"A single death or severe illness in an otherwise healthy volunteer would be unconscionable and would halt progress", they wrote.

Sinovac said earlier in July that it was starting Phase 3 trials of its potential coronavirus vaccine in Brazil, becoming one of three companies to move into the late stages in the race to develop an inoculation against the disease. The volunteers' blood samples showed that the vaccine had triggered the body to produce both antibodies and killer T-cells to combat the infection. He further said that some people have already registered for this test. These volunteers are intentionally exposed to the pathogen in a controlled laboratory setting, which means it can be finished in weeks and requires fewer people than other types of trials.

Another vaccine from competing research establishment, the State Scientific Centre "Vector", is being examined by experts to obtain permission for clinical trials.

State Innovation Minister Kate Jones yesterday revealed that Queensland had clinched the Aussies-first deal, as a hard-won condition in the contract handing UQ $10 million in taxpayer funding to fast-track research and production of the vaccine.

Regulators and experts in the USA and Europe, however, said the emergency situation could allow the interim use of an prospective vaccine or vaccines ahead of an official go ahead clearance.

The human trials of Covaxin has begun at the All India Institute of Medical Sciences, Patna.

The SARS-CoV-2 strain was isolated in NIV, Pune, and transferred to Bharat Biotech.

A total of 100 participants will be recruited by the institute, with the trials being carried out on 375 participants in the first phase.

Data compiled by Johns Hopkins University show more than 14 million cases worldwide since the start of the pandemic.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE